Emily M. Leproust Sells 2,216 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 2,216 shares of the company’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $52.70, for a total transaction of $116,783.20. Following the transaction, the chief executive officer now owns 674,718 shares of the company’s stock, valued at $35,557,638.60. This represents a 0.33 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST traded down $0.09 during trading on Tuesday, hitting $51.56. The company had a trading volume of 627,617 shares, compared to its average volume of 941,410. The company has a market cap of $3.06 billion, a P/E ratio of -14.35 and a beta of 1.82. The business’s 50-day moving average is $44.49 and its 200 day moving average is $46.51. Twist Bioscience Co. has a 52 week low of $26.51 and a 52 week high of $60.90.

Analyst Ratings Changes

A number of research firms have recently weighed in on TWST. Robert W. Baird lifted their price target on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Barclays reduced their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Leerink Partners raised their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Evercore ISI upped their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Scotiabank raised their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $51.00.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the stock. Thrivent Financial for Lutherans purchased a new stake in Twist Bioscience during the third quarter valued at about $43,992,000. Point72 Asset Management L.P. lifted its position in shares of Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after acquiring an additional 613,057 shares in the last quarter. Fred Alger Management LLC boosted its stake in Twist Bioscience by 720.7% in the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after purchasing an additional 575,080 shares during the period. State Street Corp grew its position in Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after purchasing an additional 521,272 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.